Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636749 | 0.83 | KMT2A (0.36) | SMN1; SMN2L3MBTL1PIK3CDKMT2APDK2 | |
| SCHEMBL1635359 | 0.83 | PIK3CD (0.41) | SMN1; SMN2L3MBTL1PIK3CDKMT2APOLB | |
| SCHEMBL9917278 | 0.76 | PIK3CD (0.51) | SMN1; SMN2L3MBTL1PIK3CDKMT2APOLB | |
| SCHEMBL4581970 | 0.74 | L3MBTL1 (0.48) | SMN1; SMN2L3MBTL1PIK3CDKMT2APOLB | |
| SCHEMBL9921228 | 0.72 | PIK3CD (0.47) | SMN1; SMN2L3MBTL1PIK3CDKMT2AMEN1 | |
| SCHEMBL9917276 | 0.72 | PIK3CD (0.46) | SMN1; SMN2L3MBTL1PIK3CDKMT2APDK2 | |
| SCHEMBL8524128 | 0.70 | PIK3CD (0.46) | SMN1; SMN2PIK3CDKMT2APDK2POLB | |
| SCHEMBL21988583 | 0.70 | PIK3CD (0.47) | SMN1; SMN2L3MBTL1PIK3CDKMT2APOLB | |
| SCHEMBL20579542 | 0.70 | L3MBTL1 (0.47) | SMN1; SMN2L3MBTL1PIK3CDKMT2APOLB | |
| SCHEMBL9921226 | 0.70 | L3MBTL1 (0.44) | SMN1; SMN2L3MBTL1PIK3CDKMT2APDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9052440-B2 | Chain-extended polysiloxane crosslinkers with dangling hydrophilic polymer chains | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-20140350124-A1 | CHAIN-EXTENDED POLYSILOXANE CROSSLINKERS WITH DANGLING HYDROPHILIC POLYMER CHAINS | ALCON INC. (CH) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350124-A1 | CHAIN-EXTENDED POLYSILOXANE CROSSLINKERS WITH DANGLING HYDROPHILIC POLYMER CHAINS | HACD2, HACD3, PCNA | SMN1; SMN2 2149/4885L3MBTL1 2711/4885PIK3CD 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.